MOTS-c within MT-RNR1
A peptide encoded in a region associated with ribosomal RNA: the surprise starts with its address.
The sequence in MT-RNR1
MOTS-c is a chain of 16 amino acids, with the sequence MRWQEMGYIFYPRKLR. Its genetic instructions occupy a short open reading frame within MT-RNR1, the mitochondrial 12S ribosomal RNA gene. The 2023 review of MOTS-c biology describes this unusual origin and the peptide’s roles in stress and metabolism.
I like the discovery’s small scale. The familiar mitochondrial genome contains another functional sequence, and a small peptide changes the questions that can be asked of it. That makes a better starting point than the enormous collection of outcomes now attached to its name.
The origin also helps with the NAD+ comparison. MOTS-c is a peptide; NAD+ is a dinucleotide. The two connect with cellular metabolism through different chemical roles.
Folate metabolism under stress
In the cell and animal work summarized in the review, MOTS-c inhibits the folate cycle and de novo purine biosynthesis. AICAR accumulates, activating AMPK, a sensor that helps cells respond to their energy state. In those experimental settings, this pathway connects MOTS-c with glucose handling and insulin sensitivity.
A 2018 study in human and mouse cells followed a further behavior under metabolic stress: MOTS-c moved to the nucleus and regulated nuclear gene expression in an AMPK-dependent manner, including antioxidant-response genes through NRF2 interaction. The interesting expansion here is in what a mitochondrial peptide can do inside a cell. Clinical treatment effects require evidence beyond that cellular behavior.
CK2: muscle activation, fat suppression
The 2024 CK2 study added a direct molecular target. In cell-free assays MOTS-c bound to and activated casein kinase 2. In mice, CK2 activation in muscle and suppression in fat underlay effects on muscle glucose uptake and protection against atrophy. Immobilization and high-fat-diet models supplied different tests of that relationship.
I admire the unequal tissue responses. A simple label such as ‘activator’ would lose the distinction between muscle and fat. I welcome this extra precision, even when it makes the molecule harder to summarize.
Exercise studies; circulating MOTS-c in dialysis
In the 2021 physical-performance experiments, administered MOTS-c enhanced running capacity, grip strength and gait in aged mice. The study included mice aged 2, 12 and 22 months and established exercise inducibility of endogenous MOTS-c. The administered-peptide performance results remain animal findings.
A different kind of result came from 94 people receiving chronic hemodialysis, followed for a median of 26.5 months. Circulating MOTS-c was independently associated with a combined endpoint of all-cause mortality and non-fatal cardiovascular events (Cox HR 1.004, p=0.05). Adding it to the risk model changed ROC AUC from 0.727 to 0.743.
That is a measured association with outcomes during follow-up. Nobody was assigned MOTS-c treatment in this cohort. Its possible biomarker role intrigues me precisely because measuring an endogenous molecule asks a different question from administering it.
MOTS-c cautions and prescribing
MOTS-c's caution profile is shaped by the early stage of its evidence base:
No human efficacy trials. Every claim about exogenous MOTS-c improving metabolism, performance, or aging in humans derives from animal experiments or observational biomarker studies. No interventional human efficacy trials have been published [9][10]. The hemodialysis cohort finding is an association, not a causal demonstration.
No validated human pharmacokinetics. There is no published measured human half-life, bioavailability, or dose-response for MOTS-c. Rodent doses used in studies (ranging from roughly 0.5 to 15 mg/kg per day, depending on the study) cannot be extrapolated to humans, and this site does not offer any dosing guidance.
Anti-doping status. MOTS-c is treated as a prohibited substance in elite sport. Anti-doping bodies including USADA and WADA classify MOTS-c among peptide and metabolic-modulator agents prohibited at all times; athlete use can result in sanctions. This is a concrete concern for any competitive or tested athlete considering research use [9].
Research-chemical supply. MOTS-c is sold by chemical suppliers for laboratory research only; product purity, identity, and sterility are not regulated as pharmaceuticals and vary by supplier.
Ancestry and genotype variation. A pro-diabetogenic MOTS-c mtDNA variant (m.1382A>C) and ancestry-dependent exercise responses have been described in the literature, suggesting that MOTS-c effects are not uniform across populations [10].
Small-sample and single-lab reliance. Several mechanistic and human biomarker studies are small or preliminary; some findings await independent replication in larger or more diverse cohorts.
Laboratory supply and clinical prescribing remain different routes: Promise Peptides currently prescribes MOTS-c in the prescription care described at mypromise.com. A licensed U.S. clinician examines each request and decides whether it warrants prescribing; some requests are turned down. Promise Peptides' care options are constrained by a U.S. patient's state and the treatment sought; patients outside the United States are excluded. This compounded medication has no FDA approval, and none of these access arrangements strengthen the human findings summarized here.
This site's source material does not include compiled community-anecdote reports for MOTS-c; the cautions above are drawn from the cited peer-reviewed literature.
